| Axon ID |
Name |
Description |
From price |
|
1137
|
PD180970
|
Bcr-Abl tyrosine kinase inhibitor (p210 specific) |
€120.00 |
|
1392
|
Dasatinib
|
Bcr-Abl and Src tyrosine kinase inhibitor |
€90.00 |
|
1396
|
Nilotinib
|
BCR-ABL inhibitor |
€50.00 |
|
1398
|
Sunitinib malate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€80.00 |
|
1407
|
SKI 606
|
Bcr-Abl and Src tyrosine kinase inhibitor |
€75.00 |
|
1414
|
AG 013736
|
PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor |
€50.00 |
|
1415
|
CT 53518
|
PDGFR, c-KIT and FLT3 tyrosine kinase inhibitor |
€70.00 |
|
1419
|
AB 1010
|
PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor |
€70.00 |
|
1420
|
Pazopanib hydrochloride
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€60.00 |
|
1547
|
OSI 930
|
c-Kit and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1581
|
SU 11274
|
ATP-competitive inhibitor of c-MET |
€90.00 |
|
1582
|
Foretinib
|
c-MET and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1583
|
PF 04217903 mesylate
|
c-MET tyrosine kinase Inhibitor |
€80.00 |
|
1638
|
ABT 869
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€85.00 |
|
1660
|
Crizotinib
|
c-MET Inhibitor; NPM-ALK inhibitor |
€70.00 |
|
1678
|
Regorafenib
|
Multi-kinase RTK inhibitor |
€70.00 |
|
1696
|
Quizartinib dihydrochloride
|
FLT3 inhibitor |
€90.00 |
|
1768
|
AMG 706
|
Multiple receptor tyrosine kinase inhibitor |
€105.00 |
|
1819
|
Cabozantinib S-malate
|
Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 |
€60.00 |
|
1838
|
ARQ 197
|
c-MET tyrosine kinase Inhibitor |
€90.00 |
|
1857
|
AP 24534
|
BCR-ABL kinase inhibitor (including T315I mutation) |
€80.00 |
|
1882
|
GNF 2
|
Inhibitor of Bcr-Abl tyrosine kinase |
€110.00 |
|
1891
|
SU 6668
|
Inhibitor of RTK targeting PDGFR, VEGF and FGFR |
€100.00 |
|
1914
|
SGX 523
|
ATP-competitive inhibitor of c-MET |
€120.00 |
|
1916
|
AMG 208
|
Inhibitor of c-MET receptor tyrosine kinase (RTK) |
€95.00 |
|
1959
|
Golvatinib
|
Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 |
€90.00 |
|
2121
|
INNO 406
|
Dual Bcr-Abl and Lyn kinase inhibitor |
€85.00 |
|
2123
|
DCC 2036
|
An orally active Bcr-ABL inhibitor |
€125.00 |
|
2219
|
AT 9283
|
Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) |
€85.00 |
|
2368
|
Amuvatinib
|
RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met |
€105.00 |
|
3168
|
Nilotinib hydrochloride
|
BCR-ABL inhibitor |
€70.00 |
|
3624
|
Toceranib phosphate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€60.00 |
|
2757
|
Asciminib
|
Potent and selective allosteric BCR-ABL1 inhibitor |
€120.00 |